Good bugs and bad bugs: indications and therapies for Helicobacter pylori eradication

Curr Opin Pharmacol. 2003 Oct;3(5):480-5. doi: 10.1016/s1471-4892(03)00116-4.

Abstract

The discovery of Helicobacter pylori has had a major clinical impact. Clinical research is now focused on the role of H. pylori and H. pylori eradication in the treatment of several upper gastrointestinal disorders such as non-ulcer dyspepsia, ulceration during therapy with aspirin or other anti-inflammatory drugs, the treatment of precancerous conditions of the stomach, and the prevention of gastric cancer. Triple and quadruple therapies have become the standard for H. pylori eradication. The expansion of knowledge and the development of new therapeutic modalities are likely to lead to a further implementation of H. pylori-related methods in strategies for the prevention and treatment of upper gastrointestinal disorders.

Publication types

  • Review

MeSH terms

  • Anti-Bacterial Agents / therapeutic use*
  • Anti-Inflammatory Agents, Non-Steroidal / adverse effects
  • Dyspepsia / drug therapy
  • Dyspepsia / microbiology
  • Gastritis / drug therapy
  • Gastritis / etiology
  • Gastritis / microbiology
  • Gastroesophageal Reflux / drug therapy
  • Gastroesophageal Reflux / microbiology
  • Helicobacter Infections / complications
  • Helicobacter Infections / diagnosis
  • Helicobacter Infections / drug therapy*
  • Helicobacter pylori / drug effects*
  • Humans
  • Peptic Ulcer / drug therapy
  • Peptic Ulcer / microbiology
  • Proton Pump Inhibitors
  • Stomach Neoplasms / drug therapy
  • Stomach Neoplasms / microbiology

Substances

  • Anti-Bacterial Agents
  • Anti-Inflammatory Agents, Non-Steroidal
  • Proton Pump Inhibitors